Halozyme Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Halozyme Therapeutics (HALO).

Price Target Range — 13 Quarters

Analyst Consensus — 10 Analysts

2S.Buy

5Buy

3Hold

Consensus RatingMarket Outperform# Analysts10Avg. Consensus PT$86Upside to Avg. PT-33.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 13, 2026	TD Cowen	Brendan Smith	PT Raise	Buy	$105→$130
Oct 8, 2026	JP Morgan	Jessica Fye	PT Raise	Neutral	$70→$78
Oct 8, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	PT Raise	Buy	$115→$130
Sep 2, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$115
Aug 7, 2026	Leerink Partners	David Risinger	Upgrade	Market Perform→Outperform	$83→$110
Aug 7, 2026	TD Cowen	Brendan Smith	PT Raise	Buy	$96→$105
Aug 7, 2026	Citizens	Jason N. Butler	PT Raise	Market Outperform	$92→$93
Aug 7, 2026	Wells Fargo	Mohit Bansal	PT Raise	Equal-Weight	$75→$95
Aug 7, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	PT Raise	Buy	$95→$115
Jul 21, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$95
May 12, 2026	Morgan Stanley	Vikram Purohit	PT Cut	Overweight	$96→$93
Apr 29, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	PT Raise	Buy	$90→$95
Feb 19, 2026	Benchmark	Robert Wasserman	PT Raise	Buy	$75→$90
Feb 19, 2026	Wells Fargo	Mohit Bansal	PT Raise	Equal-Weight	$65→$75
Jan 8, 2026	TD Cowen	Brendan Smith	PT Raise	Buy	$79→$90
Dec 19, 2025	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$90
Nov 28, 2025	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$90
Nov 18, 2025	Goldman Sachs	Graig Suvannavejh	PT Raise	Neutral	$54→$56
Nov 4, 2025	Citizens	Jason Butler	PT Raise	Market Outperform	$91→$92
Oct 27, 2025	JP Morgan	Jessica Fye	PT Raise	Neutral	$63→$65

Analyst Ratings News

PRO
TD Cowen Maintains Buy on Halozyme Therapeutics, Raises Price Target to $130

TD Cowen analyst Brendan Smith maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the price target from $105 to $130.

Benzinga Newsdesk

PRO
JP Morgan Maintains Neutral on Halozyme Therapeutics, Raises Price Target to $78

JP Morgan analyst Jessica Fye maintains Halozyme Therapeutics (NASDAQ:HALO) with a Neutral and raises the price target from $70 to $78.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Halozyme Therapeutics, Raises Price Target to $130

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the price target from $115 to $130.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $115 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $115 price target.

Benzinga Newsdesk

PRO
Leerink Partners Upgrades Halozyme Therapeutics to Outperform, Raises Price Target to $110

Leerink Partners analyst David Risinger upgrades Halozyme Therapeutics (NASDAQ:HALO) from Market Perform to Outperform and raises the price target from $83 to $110.

Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on Halozyme Therapeutics, Raises Price Target to $105

TD Cowen analyst Brendan Smith maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the price target from $96 to $105.

Benzinga Newsdesk

Halozyme Therapeutics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Halozyme Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
TD Cowen Maintains Buy on Halozyme Therapeutics, Raises Price Target to $130

PRO
JP Morgan Maintains Neutral on Halozyme Therapeutics, Raises Price Target to $78

PRO
HC Wainwright & Co. Maintains Buy on Halozyme Therapeutics, Raises Price Target to $130

PRO
HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $115 Price Target

PRO
Leerink Partners Upgrades Halozyme Therapeutics to Outperform, Raises Price Target to $110

PRO
TD Cowen Maintains Buy on Halozyme Therapeutics, Raises Price Target to $105

People Also Watch

People Also Watch

Halozyme Therapeutics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Halozyme Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROTD Cowen Maintains Buy on Halozyme Therapeutics, Raises Price Target to $130

PROJP Morgan Maintains Neutral on Halozyme Therapeutics, Raises Price Target to $78

PROHC Wainwright & Co. Maintains Buy on Halozyme Therapeutics, Raises Price Target to $130

PROHC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $115 Price Target

PROLeerink Partners Upgrades Halozyme Therapeutics to Outperform, Raises Price Target to $110

PROTD Cowen Maintains Buy on Halozyme Therapeutics, Raises Price Target to $105

People Also Watch

People Also Watch

PRO
TD Cowen Maintains Buy on Halozyme Therapeutics, Raises Price Target to $130

PRO
JP Morgan Maintains Neutral on Halozyme Therapeutics, Raises Price Target to $78

PRO
HC Wainwright & Co. Maintains Buy on Halozyme Therapeutics, Raises Price Target to $130

PRO
HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $115 Price Target

PRO
Leerink Partners Upgrades Halozyme Therapeutics to Outperform, Raises Price Target to $110

PRO
TD Cowen Maintains Buy on Halozyme Therapeutics, Raises Price Target to $105